title: Development and characterization of recombinant ovine coagulation factor VIII.
abstract: Animal models of the bleeding disorder, hemophilia A, have been an integral component of the biopharmaceutical development process and have facilitated the development of recombinant coagulation factor VIII (fVIII) products capable of restoring median survival of persons with hemophilia A to that of the general population. However, there remain several limitations to recombinant fVIII as a biotherapeutic, including invasiveness of intravenous infusion, short half-life, immunogenicity, and lack of availability to the majority of the world's population. The recently described ovine model of hemophilia A is the largest and most accurate phenocopy. Affected sheep die prematurely due to bleeding-related pathogenesis and display robust adaptive humoral immunity to non-ovine fVIII. Herein, we describe the development and characterization of recombinant ovine fVIII (ofVIII) to support further the utility of the ovine hemophilia A model. Full-length and B-domain deleted (BDD) ofVIII cDNAs were generated and demonstrated to facilitate greater biosynthetic rates than their human fVIII counterparts while both BDD constructs showed greater expression rates than the same-species full-length versions. A top recombinant BDD ofVIII producing baby hamster kidney clone was identified and used to biosynthesize raw material for purification and biochemical characterization. Highly purified recombinant BDD ofVIII preparations possess a specific activity nearly 2-fold higher than recombinant BDD human fVIII and display a differential glycosylation pattern. However, binding to the carrier protein, von Willebrand factor, which is critical for stability of fVIII in circulation, is indistinguishable. Decay of thrombin-activated ofVIIIa is 2-fold slower than human fVIII indicating greater intrinsic stability. Furthermore, intravenous administration of ofVIII effectively reverses the bleeding phenotype in the murine model of hemophilia A. Recombinant ofVIII should facilitate the maintenance of the ovine hemophilia A herd and their utilization as a relevant large animal model for the research and development of novel nucleic acid and protein-based therapies for hemophilia A.
authors.affiliation: Graduate Program in Molecular and Systems Pharmacology, Emory University, Atlanta, Georgia, United States of America.
authors.forename: Philip M
authors.initials: PM
authors.lastname: Zakas
authors.forename: Bagirath
authors.initials: B
authors.lastname: Gangadharan
authors.forename: Graca
authors.initials: G
authors.lastname: Almeida-Porada
authors.forename: Christopher D
authors.initials: CD
authors.lastname: Porada
authors.forename: H Trent
authors.initials: HT
authors.lastname: Spencer
authors.forename: Christopher B
authors.initials: CB
authors.lastname: Doering
mesh_terms: D000818:Animals; D002460:Cell Line; D006224:Cricetinae; D005169:Factor VIII / Q000096:biosynthesis* / Q000737:chemistry / Q000302:isolation & purification / Q000627:therapeutic use; D006467:Hemophilia A / Q000188:drug therapy; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D011134:Polysaccharides / Q000378:metabolism; D011485:Protein Binding; D055503:Protein Multimerization; D017434:Protein Structure, Tertiary; D059748:Proteolysis; D011994:Recombinant Proteins / Q000096:biosynthesis* / Q000737:chemistry / Q000302:isolation & purification / Q000627:therapeutic use; D017384:Sequence Deletion; D034561:Sheep, Domestic / Q000378:metabolism*; D013917:Thrombin / Q000378:metabolism; D014841:von Willebrand Factor / Q000378:metabolism
chemical_list: D011134:Polysaccharides; D011994:Recombinant Proteins; D014841:von Willebrand Factor; D005169:Factor VIII; D013917:Thrombin